IP for VR1 antagonists (follow-up of previous post):
appft1.uspto.gov
Abbott
appft1.uspto.gov
Merck (pre NRGN?)
appft1.uspto.gov
Novartis
appft1.uspto.gov
GSK
appft1.uspto.gov
J&J, with intersting snip:
"Walpole and colleagues at Sandoz reported on the first competitive antagonist of the sensory neuron excitants capsaicin and resineriferatoxin (Walpole, C. S. J. et. al., J. Med. Chem. 1994, 37,1942). Subsequently, capsazepine has been shown to be a vanilloid receptor antagonist. Capsazepine, however, is not naphthol, quinoline and isoquinoline-derived. Jee Woo Lee and colleagues at Pacific Corporation disclosed thiocarbamic acid derived VR1 antagonists in WO0216317A1 and vanilloid receptor modulators in WO0216318A1 and WO0216319A1 but these applications do not disclose or describe N-naphthol, quinoline and isoquinoline-derived N'-benzylic ureas. Hutchinson and colleagues at Neurogen describe diaryl piperazinyl ureas and related compounds as capsaicin receptor ligands in WO02082212A1 but N-naphthol, quinoline and isoquinoline-derived N'-benzylic ureas are not covered. Scientists at the Universidad Miguel Hernandez in Alicante, the Universidad de Valencia and the Consejo Superior de Investigaciones Cientificas (CSIC) in Barcelona have used a combinatorial chemistry-based approach to discover compounds that modulate the vanilloid VR1 receptor and have disclosed two trialkylglycine-based compounds as noncompetitive VR1 channel blockers (Garcia-Martinez, C. et al. Proc Natl Acad Sci USA 2002, 99(4): 2374) but none are naphthol, quinoline and isoquinoline-derived."
emphasis mine
I couldn't seem to find this Hutchinson patent app at the EPO. Not sure what I'm doing wrong. Rick, I know you're good at this, help!
Edit: spoke too soon; it just took 3 tries to find which keywords worked . . . sorry to bother you . . .
v3.espacenet.com
Hutchinson/Neurogen patent app.
Cheers, Tuck |
